Addressing the unmet medical needs of cancer patients through the selective blocking of two novel pharmacological targets


ABOLOGIX is developing best-in-class monoclonal antibodies by blocking the Junction Adhesion Molecule JAM-C and the extracellular matrix-related protein Olfactomedin-like protein 3 (Olfml3).

 

Blocking JAM-C is a novel approach for the treatment of non-Hodgkin´s lymphoma.

 

Olfml3 is a proangiogenic factor in the tumor microenvironment, being released by endothelial cells and pericytes. Blocking Olfml3 can lead to a new generation of angiogenic inhibitors.

 

The company is based in Geneva (Switzerland) and it is a spin-out from the laboratories of Profs. Beat Imhof and Thomas Matthes at the Université de Genève and the Hôpitaux Universitaires de Genève.

 

 

Copyright © 2020 ABOLOGIX